Nicotine Dependence Clinical Trial
Official title:
Evaluation of Plasma Nicotine, Carbon Monoxide, Heart Rate, Craving and Withdrawal After Acute Use of the NJOY King E-Cigarette in the Clinic, Following a One-Week Actual Use Pilot Study
Electronic Nicotine Delivery Systems (ENDS), commonly referred to as electronic cigarettes
have gained in popularity over the last several years. The technology used to manufacture
ENDS has been evolving rapidly with a variety of delivery mechanisms, nicotine content,
e-liquids and flavorings. Only in the last few years have researchers begun to examine the
health risks and benefits, nicotine blood levels, patterns of use, likability, and craving
and withdrawal relief of ENDS. These studies have shown great variability in nicotine
delivery, effects on heart rate, and relief of craving or withdrawal among various ENDS
brands among tobacco cigarette smokers.
This study will test a new generation ENDS, the NJOY King Bold (NJOY, Scottsdale, AZ). It is
a single use unit that resembles a traditional cigarette and delivers approximately 150
puffs. The cartridge inside contains 26 milligrams of nicotine.
Our primary objective is to evaluate the short-term effects of using the NJOY Kings ENDS on
heart rate, carbon monoxide and blood nicotine levels and well as on craving for cigarettes
and nicotine withdrawal. Our secondary objective is to evaluate the subject's usage patterns
for cigarettes and NJOY King ENDS during a one-week period in which they can use each
freely.
The study includes three visits to the clinic spaced approximately one week apart. Subjects
who pass the screening visit will return to the clinic for Visit 2 in which they will sample
the NJOY King ENDS for about 20 minutes before taking home enough to last till Visit 3, one
week later. They will be instructed to use as many or as few as they like during the week.
Subjects will keep a daily diary of number of tobacco cigarettes smoked and number of
e-cigarette puffs taken. Subjects will return to the clinic for Visit 3 after 12 hours of
abstinence from any form of nicotine in order to assure that they have no nicotine left in
their bloodstream. Eligible subjects will then participate in two series of 10 puffs of NJOY
Kings spaced one hour apart. During the 2.5 hours of the testing day, the following will be
measured: 1) heart rate, 2) carbon monoxide, 3)blood will be sampled for nicotine levels, 4)
craving for cigarettes and nicotine withdrawal symptoms will be assessed.
n/a
Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05176418 -
IV Pulsed-Nicotine as a Model of Smoking: The Effects of Dose and Delivery Rate
|
Early Phase 1 | |
Completed |
NCT04084210 -
Impact of Alternative Nicotine-Delivery Products on Combustible Cigarette Use
|
Phase 2 | |
Completed |
NCT04043728 -
Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study
|
N/A | |
Withdrawn |
NCT03707600 -
State and Trait Mediated Response to TMS in Substance Use Disorder
|
N/A | |
Recruiting |
NCT03999099 -
Targeting Orexin to Treat Nicotine Dependence
|
Phase 1 | |
Completed |
NCT03847155 -
Prevention of Nicotine Abstinence in Critically Ill Patients After Major Surgery
|
N/A | |
Completed |
NCT02840435 -
Study on Sit to Quit Phone Intervention
|
N/A | |
Completed |
NCT02139930 -
Project 2: Strategies for Reducing Nicotine Content in Cigarettes
|
N/A | |
Completed |
NCT01982110 -
A Mindfulness Based Application for Smoking Cessation
|
N/A | |
Completed |
NCT01926626 -
Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers
|
Phase 2 | |
Completed |
NCT01569490 -
Striving to Quit: First Breath
|
N/A | |
Completed |
NCT01685996 -
Zonisamide Augmentation of Varenicline Treatment for Smoking Cessation
|
Phase 1/Phase 2 | |
Completed |
NCT01632189 -
The Effect of Varenicline on D2/D3 Receptor Binding in Smokers
|
N/A | |
Withdrawn |
NCT01569477 -
Striving to Quit-Wisconsin Tobacco Quit Line
|
N/A | |
Active, not recruiting |
NCT01182766 -
New Treatment for Alcohol and Nicotine Dependence
|
Phase 2/Phase 3 | |
Completed |
NCT00996034 -
Nicotine Vaccination and Nicotinic Receptor Occupancy
|
Phase 2 | |
Completed |
NCT01061528 -
Coping Skills Treatment for Smoking Cessation
|
N/A | |
Completed |
NCT01943994 -
Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study
|
N/A | |
Withdrawn |
NCT01589081 -
Effects of Progesterone on IV Nicotine-Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effect
|
N/A | |
Suspended |
NCT01636336 -
Effects of Progesterone on Smoked Nicotine Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effects
|
N/A |